Trulicity 1.5 Mg Injection 4 Pens

Trulicity 1.5 Mg Injection 4 Pens

Description:

Trulicity 1.5 mg/0.5 ml Injection (4 pre-filled pens) is a prescription diabetes medicine containing dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is used once weekly as an adjunct to diet and exercise to improve blood sugar (glycemic) control in adults with type 2 diabetes mellitus. Each pre-filled pen delivers a fixed dose of dulaglutide via subcutaneous injection, supporting long-term diabetes management and helping reduce the risk of diabetes-related complications when used as part of a comprehensive treatment plan prescribed by a healthcare professional.

Indications:

• Indicated for adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control.
• May be used as monotherapy when metformin is not tolerated or contraindicated, or in combination with other oral antidiabetic medicines or insulin as directed by a physician.
• Helps reduce elevated fasting and postprandial blood glucose levels.
• Not indicated for type 1 diabetes mellitus.
• Not indicated for the treatment of diabetic ketoacidosis.

Active Ingredients / Key Components:

• Dulaglutide – 1.5 mg per 0.5 ml pre-filled pen (glucagon-like peptide-1 (GLP-1) receptor agonist).
• Each pack contains 4 pre-filled, single-dose pens for subcutaneous injection.
• Other excipients (such as buffering agents, stabilizers, and water for injection) are present but specific excipient names and concentrations , please check the product leaflet or the manufacturer’s official website.

Dosage & Administration / How to Use:

• Usual adult dose (type 2 diabetes): 1.5 mg dulaglutide administered once weekly by subcutaneous injection, or as prescribed by the treating physician.
• Inject subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites with each dose to reduce the risk of local irritation.
• Trulicity can be taken with or without food and at any time of the day, but should be administered on the same day each week.
• If a dose is missed and the next scheduled dose is at least 3 days (72 hours) away, administer the missed dose as soon as possible. If less than 3 days remain until the next dose, skip the missed dose and resume the regular schedule. Do not inject two doses within 3 days of each other.
• Use each pen only once and dispose of it safely in a sharps container after injection.
• Do not mix Trulicity with insulin in the same syringe. If used with insulin, administer as separate injections and never at the same injection site.
• Always follow the specific instructions provided by your healthcare provider and the patient information leaflet included with the product.

Clinical Benefits:

• Improves glycemic control in adults with type 2 diabetes by enhancing glucose-dependent insulin secretion and reducing glucagon secretion.
• Provides convenient once-weekly dosing, which may support better treatment adherence compared to multiple daily injections.
• Helps lower fasting and post-meal blood glucose levels, contributing to improved long-term HbA1c control.
• May support modest weight reduction in some patients as part of an overall diabetes management plan including diet and exercise (individual results may vary).

Warnings & Contraindications:

• For use only under medical supervision. Prescription medicine for type 2 diabetes mellitus.
• Contraindicated in patients with a known hypersensitivity to dulaglutide or any of the excipients.
• Not indicated for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
• Use with caution in patients with a history of pancreatitis; discontinue and seek medical attention if severe abdominal pain occurs that may radiate to the back.
• Use with caution in patients with severe gastrointestinal disease, including severe gastroparesis, as GLP-1 receptor agonists can slow gastric emptying.
• Monitor renal function in patients with existing renal impairment, especially if severe gastrointestinal adverse reactions (e.g., vomiting, diarrhea) occur.
• May increase the risk of hypoglycemia when used in combination with insulin or insulin secretagogues (e.g., sulfonylureas); dose adjustments of concomitant therapy may be required.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding; safety data in pregnancy and lactation are limited.
• Consult your doctor before use if you have thyroid disease, pancreatic disease, severe gastrointestinal disorders, kidney disease, liver disease, or are taking other antidiabetic or systemic medications.
• Do not share injection pens with others to avoid transmission of infections, even if the needle is changed.
• Keep out of reach of children.
• Not intended to diagnose, treat, cure, or prevent any disease outside of its approved medical indications.

Side Effects:

• Common side effects may include nausea, vomiting, diarrhea, abdominal pain, decreased appetite, indigestion, and fatigue. These are often mild to moderate and may decrease over time as the body adjusts.
• Other possible side effects include injection site reactions (redness, itching, swelling), constipation, and mild hypoglycemia, especially when used with insulin or sulfonylureas.
• Serious but less common side effects may include pancreatitis (severe, persistent abdominal pain, possibly radiating to the back), severe allergic reactions (rash, itching, swelling of face/tongue/throat, difficulty breathing), and significant kidney function changes secondary to dehydration from severe gastrointestinal symptoms.
• Seek immediate medical attention if you experience signs of severe allergic reaction, severe abdominal pain, or symptoms of severe hypoglycemia (confusion, fainting, seizures).
• Report any unusual or persistent side effects to your doctor or pharmacist promptly.

Storage Instructions:

Store Trulicity pre-filled pens in a refrigerator at 2–8°c. Do not freeze. If a pen has been frozen, do not use it. Keep the pens in the original carton to protect from light. If necessary, Trulicity pens may be kept at room temperature (not above 30°c) for a limited period as specified in the official product leaflet; refer to the package insert for exact allowable time out of refrigeration. Keep out of reach of children. Do not use after the expiry date printed on the pack.

Specifications:

• Form: Pre-filled single-dose injection pen for subcutaneous use.
• Strength: 1.5 mg dulaglutide per 0.5 ml solution.
• Pack size: 4 pre-filled pens (4 weekly doses for most patients, depending on prescription).
• Route of administration: Subcutaneous injection (abdomen, thigh, or upper arm).

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.